Adding elotuzumab to myeloma treatment decreases risk of disease progression

the ONA take:

The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced risk of disease progression or death by 30% in patients with relapsed or refractory multiple myeloma, according to a new study published online in the New England Journal of Medicine and presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, this week.

For the phase III ELOQUENT-2 trial, researchers randomly assigned 646 patients with relapsed or refractory multiple myeloma to receive lenalidomide plus dexamethasone with or without elotuzumab.

Results showed that after a median follow-up of 24.5 months, the 1-year progression-free survival rate was 68% in the elotuzumab group versus 57% in the control group. The 2-year progression-free survival rates were 41% and 27%, respectively. Researchers found that median progression-free survival was 19.4 months in the elotuzumab group compared with 14.9 months in the control group.

In regard to safety, the most common grade 3 or 4 adverse events in both groups were fatigue, lymphocytopenia, neutropenia, and pneumonia. In the elotuzumab group, 10% of patients experienced infusion-related reactions, of which the majority were grade 1 or 2.

Adding elotuzumab to myeloma treatment decreases risk of disease progression
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
READ FULL ARTICLE From New England Journal of Medicine
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs